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EXPERIMENTAL WEITOGENIC ANTIGENS AND THEIR ROLE 
IN CLINICAL WEITIS 
D. BenEzra and G. Maftzir, Department Of 
Ophthalmology, Hadassah University Hospital, 
Jerusalem, Israel 
PlXDOSO: TO assess the possible role Of 
experimental uveitogenic antigens (S-Ag, IRPB and 
recoverin) in human uveitis. 
Methods : Patients suffering from non-infectious 
bilateral UVeitiS and from the Ocular type of 
Behcet's disease were included in this study. 
Patients’ lymphocytes were tested for their 
possible in vitro anamnestic immune ~~SpClllS~ 
(specific blast transformation) to S-Ag, IRBP ;;i 
recoverin. The tests were carried out 
recorded in a masked manner. 
Results: Lymphocytes obtained from patients 
showed an unexpectedly low incidence of IXSpOtlSe 
towards SAg and IRBP. This .low incidence of 
specific response was only slightly higher than 
that observed for the group of healthy volunteers 
included as controls. To recoverin, there was no 
specific response of either the patients’ 
lymphocytes or those of healthy controls. 
conclusions: These data may be interpreted to 
indicate: 
antigens (52; 
The experimental uveitogenic 
IRBP and recoverin) may 
role in the uveitis observed in humans. 
Play a 
However, 
the sensitized lymphocytes “home” to the eye and 
therefore are not detected in the circulation. b) 
The experimental uveitogenic antigens known to 
date do not play a major role in the uveitis as 
observed in humans. 
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PREDICTION OF IMMUNOSUPPRESSIVE TREATMENT OUTCOME 
IN WEITIS 
D. BenEzra, G. Maftzir, and E. Cohen, Department 
of Ophthalmology, Hadassah University Hospital, 
Jerusalem, Israel 
P"rPOSe: TO evaluate the possibility of 
predicting the optimal initial dose and treatment 
outcome in patients suffering from severe chronic 
non-infectious bilateral uveitis. 
Methods: Ten patients suffering from non- 
infectious chronic bilateral uveitis were included 
in this pilot study. Blood was withdrawn before 
the initiation of treatment. The +ymphqcytes Were 
isolated, cultured in microplates and stimulated 
with Concanavalin A in the presence of various 
concentrations of Cyclosporin A (CsA). According 
to the extent of CsA inhibition in vitro, a scheme 
for an optimal initial treatment regimen was 
devised and carried out. 
&f&l&: Patients showing a higher sensitivity to 
the presence of CfA in Vitro tended to respond 
clinically to a lower initial dbse of the drug. 
Also, a decrease in the intensity of intraocular 
inflammation was observed after a shorter period 
of treatment in these patients. Furthermore, it 
I*=* found that the clinical response was best 
correlated with the ability of the patients' Serum 
(under treatment) to influence the extent of blast 
transformation of lymphocytes obtained from 
healthy volunteers. 
Conclusion: These preliminary data demonstrate 
that the in vitro reSDO"Se of 
lymphocytes can be a useful-tool 
patients' 
for predicting 
the clinical severe 
uveitis. 
response c,f patients with 
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MANAGEMENT OF SYMPATHETIC OPHTALMIA: A REVIEW 
OF 11 CASES. 
LOUVETB. REUX I. FARDEAU C. BREZIN A. and LE HOANG P. 
Service d’ophtalmologie. hopital Piti&Sulp&riere (Paris) I. 
METHODS; Eleven cases of qmpalheu< 0~1~~nlrn1.1 \\urc 
retrospectively reviewed. The mezul follo\x,-up \\a\ 10 mo11lh\ 
(range from 8 to 51 months). 
RESULTS: Nine patients were males, and 1 females. I hc 
average age was 50 years (range from 23 to 67). The diagnosis 
was made on clinical history of granulomnlous weltis 
(panuveitis in 10 cases, 3nrerior u\ eitis il l I cclsc). ocurrinl: 
after 3 perforating ocular injur) (7 cases), illlrcl-ocul3r 
surgery (3 cases), or multiple traumits in i( abe 01 umgcI111.11 
microphtalmia. The ~nsef of the weitis occurred from I 10 liZ 
months (21 years) after the inciring trdumn (mean= 72 
months). Tuberculos% ssrcadosis, Icpros), and Vugl- 
Koyanagi-Harada !vere ruled out. All pnticnls rccei\cd high 
doses of systemic steroids. in combination wirh colchicine in i 
cases, with immunosuppressive drugs in 3 cases (c?clo\por~nc 
in 2 cases rind cyclophosphamide in 1 case). In 7 C:ISCS, ~hc 
exciting eyes were not enucleated, bum the? did 111 -I caws I.4 
during the uveiris). Five of the 7 non-enuclca~cd p.uicol\ alnd 4 
of the 4 enuclcatcd patienls rctaincd a \i\uaI &uil? 111 0.0 OI- 
better in the sympathizing qe. 
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TITLE : VOGT-KOYANAGI HARADA SYNDROME : 
ANALYSIS OF VISUAL PROGNOSIS AND TREATMENT 
(ABOUT 13 CASES) 
LAALAMI S., REUX I., CASSOUX N., FARDEAU C.AND 
LEHOANG P. 
Service d’Ophtalmologie,Grouppe Hospitalier Piti&&zip&i&e, Park, France. 
Putpose : To evaluate diagnostic criteria, treatment and visual prognosis of 
patimts with Vogt-Koyanagi-Hamda syndrome. 
Pafients : We rev iewcd data from 13 consecutive patients with Vogt- 
Koyanagi-Haada syndrome who werenfemdto theeyeclnic b3ween 
january1988anddecember1994. 
RcsuUs:ElevenwomcnandZmenwrreconcemed. Theaverageapwas 
35 years (14 to 61). l'be chief presenting eom@in was an hqmtant loss of 
visioninoneeye(lcase)orinbotheyes (12cascs). Ineverycase,theh&ial 
visual acuity was wo~than 4/10, Painnod 6. The diagoosis was made on 
ocular and extraocular signs and examinations. The ocular manifestations 
included cells in anterior chamber (IO cases), saws r&al detachment (8 
cases). papilledema (9 casts), and retinaI edema (3 eases). Extwxula~ signs 
and examinations were headache (5 eases), dysacousin with anormal 
audiogmmm (4 cases) and pleiocytosis in cerebrospinal fluid (8 cases). 
AIopecia (2 casts), poliosis (2 cases) and vitiligo (1 case) were rare. All 
pzltim wem treated with high doses of systmie com;costcrdids with 
tapeting dosage. In 3 caw., azathioprine was necessary. In 15 eye srrzl 
after 6 months of ucatmcnt, vlmll acuity was hater dm 7/10 Painaod 3. 
Relapse with corti~ndance was no&d in 10 casts. Complications were 
fmnent (chomSdaI neovasctdar menkane in 3 cases. cataract in 3 cases and 
ek&ion‘of inkmcolar &vedsa in 2 cases) 
Concluions : Early lugh doses systemic corticosteroId therapy followd 
by a very slow gradual mperh~g of drug dosage, and close follow-up bring 
generally good results in Vogt-Koyanagi-Harsda syndrome but chronical 
come and complications ticct frcsucntly the visual pmposis. 
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